Retrospective evaluation of HIV diagnostic algorithm as a single center


Appak Ö., Özarslan D., Sayıner A. A.

26th Annual Conference of the European Society for Clinical Virology, Frankfurt, Germany, 18 - 21 September 2024, pp.267-268, (Summary Text)

  • Publication Type: Conference Paper / Summary Text
  • City: Frankfurt
  • Country: Germany
  • Page Numbers: pp.267-268
  • Dokuz Eylül University Affiliated: Yes

Abstract

AIM: This study aimed to evaluate the effectiveness of the current HIV diagnostic algorithm.

METHODS: In accordance with CDC algorithm, our laboratory uses Architect. HIVAg/Ab for screening, Geenius™

HIV1/2 and Artus. HIVirus-1 QS-RGQ for confirmation. The Geenius™ test was used as a reflex and the HIV-1-

RNA required clinician order.

RESULTS: HIVAg/Ab test was performed in 82,882 sera and found to be reactive in 262 (0.3%). HIV-antibody

confirmatory testing was performed on 79% of samples with reactive screening test, and the presence of HIV-1

antibodies was confirmed in 51% (105/206). Half of the samples with positive-screening but negative-antibody

confirmatory result were tested for HIV1-RNA and viremia was detected in 5, confirming acute HIV-1 infection. HIV1-

RNA was not ordered for 49 samples with positive-screening and negative antibody-confirmation test,16 of these

were considered as false-reactive by the clinician. The Geenius assay result was indeterminate in 1.45% (3/206) of the

samples. In the algorithm, the number of Geenius tests would have been reduced by 25% if HIV1-RNA had been applied

as a reflex test to HIV-Ag/Ab positive samples and Geenius testing had been performed on RNA negative samples

CONCLUSIONS: A retrospective analysis showed that the HIV diagnostic algorithm was not fully implemented. An

important factor was that clinicians did not order HIV1-RNA-PCR from ELISA reactive and Geenius test negative

patients. It is predicted that the use of HIV1-RNA-PCR as a reflex test in HIV-Ag/Ab positive samples will provide

earlier diagnosis and the use of fewer Geenius test will reduce uncertain results and diagnostic cost.

SOURCES OF FUNDING: none.